Sertraline not effective for depression in NDD-CKD

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Sertraline (Zoloft) does not significantly improve symptoms of major depressive disorder (MDD) in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD).

Why this matters

  • Depression is 4-fold more common in CKD than the general population.
  • Patients with CKD are typically excluded from clinical trials.

Study design

  • Double-blind, randomized multicenter CAST trial of 201 patients (mean age, 58.2 y; 27% female) with stage IIIA (11%), IIIB (36%), IV (36%), or V (17%), NDD-CKD, and MDD.
  • Patients received sertraline or placebo for 12 wk.
  • Primary endpoint was change in 16-item Quick Inventory of Depression Symptomatology-Clinician Rated (QIDS-C16).
  • Funding: National Institute of Diabetes and Digestive and Kidney Diseases, Department of Veterans Affairs, University of Texas Southwestern Medical Center, NIH, National Institute of Mental Health.

Key results

  • Mean baseline QIDS-C16 score was similar between groups (14.0±2.4 and 14.1±2.4).
  • In primary analysis (n=193), sertraline and placebo achieved similar changes in QIDS-C16 (–4.1 vs –4.2; Δ=0.1; 95% CI, –1.1 to 1.3; P=.82).
  • Changes in patient-reported overall health on the Kidney Disease Quality of Life Survey were likewise similar (median, 0 for both; P=.61).
  • Sertraline was tied to a higher incidence of nausea/vomiting (22.7% vs 10.4%; P=.03) and diarrhea (13.4% vs 3.1%; P=.02).

Limitations

  • Lack of long-term data.